If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> December 2019<br /> + ONCOLOGY<br /> Boosting Cancer Immunotherapies with<br /> Optical Biosensor Nanotechnologies<br /> + NEUROLOGY<br /> A Case of Lance-Adams Syndrome Post<br /> Vol 4.4 ISSN: 2397-6764 Life-Threatening Bronchial Asthma<br /> + CARDIOLOGY<br /> Cardiovascular Complications in<br /> Pre-eclampsia: Can they be Predicted<br /> Electrocardiographically?<br /> + EDITOR'S PICK<br /> Identifying Shared Features and Addressing<br /> Common Challenges in Clinical Trials for Chronic<br /> Inflammatory Diseases: An Overview<br /> emjreviews.com<br /> SHARED RESULTS SHARED RELIEF<br /> NOW ALSO APPROVED FOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AGED 12—17<br /> First and only therapy that<br /> specifically targets IL-4<br /> and IL-13, key drivers of<br /> persistent underlying<br /> Type 2 inflam<a title="EMJ 4.4 2019 page 1" href="http://viewer.zmags.com/publication/385363a6?page=1"> December 2019 + ONCOLOGY Boosting Cancer Immunot</a> <a title="EMJ 4.4 2019 page 2" href="http://viewer.zmags.com/publication/385363a6?page=2"> SHARED RESULTS SHARED RELIEF NOW ALSO APPROV</a> <a title="EMJ 4.4 2019 page 3" href="http://viewer.zmags.com/publication/385363a6?page=3"> CONFIDENCE STARTS WITH CLEARANCE Kyntheum® (brod</a> <a title="EMJ 4.4 2019 page 4" href="http://viewer.zmags.com/publication/385363a6?page=4"> Contents + EDITORIAL BOARD </a> <a title="EMJ 4.4 2019 page 5" href="http://viewer.zmags.com/publication/385363a6?page=5"> “EMJ 4.4 is a celebration of tri</a> <a title="EMJ 4.4 2019 page 6" href="http://viewer.zmags.com/publication/385363a6?page=6"> Editorial Board Editor-in-Chief Prof Markus Peck-</a> <a title="EMJ 4.4 2019 page 7" href="http://viewer.zmags.com/publication/385363a6?page=7"> Aims and Scope The European Medical Journal (EMJ)</a> <a title="EMJ 4.4 2019 page 8" href="http://viewer.zmags.com/publication/385363a6?page=8"> EMJ 4.4 Chief Executive Officer Spencer Gore</a> <a title="EMJ 4.4 2019 page 9" href="http://viewer.zmags.com/publication/385363a6?page=9"> Welcome The succession of publications in 2019 he</a> <a title="EMJ 4.4 2019 page 10" href="http://viewer.zmags.com/publication/385363a6?page=10"> IN YOUR PATIENTS WITH SEVERE UNCONTROLLED ASTHMA </a> <a title="EMJ 4.4 2019 page 11" href="http://viewer.zmags.com/publication/385363a6?page=11"> Foreword Dear Colleagues, It is my great pleasure</a> <a title="EMJ 4.4 2019 page 12" href="http://viewer.zmags.com/publication/385363a6?page=12"> PSA doubling time of ≤10 months in nmCRPC despite</a> <a title="EMJ 4.4 2019 page 13" href="http://viewer.zmags.com/publication/385363a6?page=13"> PUSH BACK EARLY, PLAN FOR THEIR FUTURE �CHOOSE�ER</a> <a title="EMJ 4.4 2019 page 14" href="http://viewer.zmags.com/publication/385363a6?page=14"> Management of Moderate-to-Severe Atopic Dermatiti</a> <a title="EMJ 4.4 2019 page 15" href="http://viewer.zmags.com/publication/385363a6?page=15"> and lack of disease control. Sustained control of</a> <a title="EMJ 4.4 2019 page 16" href="http://viewer.zmags.com/publication/385363a6?page=16"> Signs AD skin lesions Symptoms Severe pruritu</a> <a title="EMJ 4.4 2019 page 17" href="http://viewer.zmags.com/publication/385363a6?page=17"> commonly available AD treatments; adult patients </a> <a title="EMJ 4.4 2019 page 18" href="http://viewer.zmags.com/publication/385363a6?page=18"> herpetic skin infections in CHRONOS was lower in </a> <a title="EMJ 4.4 2019 page 19" href="http://viewer.zmags.com/publication/385363a6?page=19"> A Mean EASI (SE) 40 35 30 25 20 15 10 5 0</a> <a title="EMJ 4.4 2019 page 20" href="http://viewer.zmags.com/publication/385363a6?page=20"> Advances in the Management of Moderate-to-Severe </a> <a title="EMJ 4.4 2019 page 21" href="http://viewer.zmags.com/publication/385363a6?page=21"> at study baseline, 34.0% reported aller</a> <a title="EMJ 4.4 2019 page 22" href="http://viewer.zmags.com/publication/385363a6?page=22"> centre-based studies, and case studies will furth</a> <a title="EMJ 4.4 2019 page 23" href="http://viewer.zmags.com/publication/385363a6?page=23"> 35. de Bruin-Weller M et al. Disease </a> <a title="EMJ 4.4 2019 page 24" href="http://viewer.zmags.com/publication/385363a6?page=24"> Improving Intravenous Immunoglobulin Dosing in </a> <a title="EMJ 4.4 2019 page 25" href="http://viewer.zmags.com/publication/385363a6?page=25"> Intravenous Immunoglobulin Dosing in Guillain</a> <a title="EMJ 4.4 2019 page 26" href="http://viewer.zmags.com/publication/385363a6?page=26"> Severe GBS No impr</a> <a title="EMJ 4.4 2019 page 27" href="http://viewer.zmags.com/publication/385363a6?page=27"> Mild GBS </a> <a title="EMJ 4.4 2019 page 28" href="http://viewer.zmags.com/publication/385363a6?page=28"> dose infusion frequency for IVIG of ‘every </a> <a title="EMJ 4.4 2019 page 29" href="http://viewer.zmags.com/publication/385363a6?page=29"> daily living’ outcome tool, either Inflammatory Ne</a> <a title="EMJ 4.4 2019 page 30" href="http://viewer.zmags.com/publication/385363a6?page=30"> count (0.35 g/L) was normal, and MRI of roots and</a> <a title="EMJ 4.4 2019 page 31" href="http://viewer.zmags.com/publication/385363a6?page=31"> treatment, corticosteroids are not recommended, t</a> <a title="EMJ 4.4 2019 page 32" href="http://viewer.zmags.com/publication/385363a6?page=32"> in Guillain-Barré syndrome with poor 15. pro</a> <a title="EMJ 4.4 2019 page 33" href="http://viewer.zmags.com/publication/385363a6?page=33"> Anticipate Your Next Move in Chronic Myeloid </a> <a title="EMJ 4.4 2019 page 34" href="http://viewer.zmags.com/publication/385363a6?page=34"> Introduction The significant advances in the </a> <a title="EMJ 4.4 2019 page 35" href="http://viewer.zmags.com/publication/385363a6?page=35"> 100 80 Patients (%) 40 20 0 60 Resista</a> <a title="EMJ 4.4 2019 page 36" href="http://viewer.zmags.com/publication/385363a6?page=36"> References 1. Bower H et al. Life expectancy</a> <a title="EMJ 4.4 2019 page 37" href="http://viewer.zmags.com/publication/385363a6?page=37"> Integrating Selective Targeted Monoclonal </a> <a title="EMJ 4.4 2019 page 38" href="http://viewer.zmags.com/publication/385363a6?page=38"> progressive decline in lung function, and all-cau</a> <a title="EMJ 4.4 2019 page 39" href="http://viewer.zmags.com/publication/385363a6?page=39"> Dupilumab Effect on Lung Funct</a> <a title="EMJ 4.4 2019 page 40" href="http://viewer.zmags.com/publication/385363a6?page=40"> Patients with uncontrolled, moderate-to-severe as</a> <a title="EMJ 4.4 2019 page 41" href="http://viewer.zmags.com/publication/385363a6?page=41"> Baseline IgE subgroups Dupilumab 200 mg q2w Wee</a> <a title="EMJ 4.4 2019 page 42" href="http://viewer.zmags.com/publication/385363a6?page=42"> Match placebo for dupilumab 200 mg q2w </a> <a title="EMJ 4.4 2019 page 43" href="http://viewer.zmags.com/publication/385363a6?page=43"> Dupilumab Efficacy in Asthma Patients wi</a> <a title="EMJ 4.4 2019 page 44" href="http://viewer.zmags.com/publication/385363a6?page=44"> References 1. Peters SP et al. Uncontrolled </a> <a title="EMJ 4.4 2019 page 45" href="http://viewer.zmags.com/publication/385363a6?page=45"> Identifying Shared Features and Addressing Co</a> <a title="EMJ 4.4 2019 page 46" href="http://viewer.zmags.com/publication/385363a6?page=46"> INTRODUCTION Chronic inflammatory diseases (CID) e</a> <a title="EMJ 4.4 2019 page 47" href="http://viewer.zmags.com/publication/385363a6?page=47"> different patient populations receiving the same </a> <a title="EMJ 4.4 2019 page 48" href="http://viewer.zmags.com/publication/385363a6?page=48"> heavily rely on assessments performed by the inve</a> <a title="EMJ 4.4 2019 page 49" href="http://viewer.zmags.com/publication/385363a6?page=49"> Table 1: Assessments of chronic inflammatory disea</a> <a title="EMJ 4.4 2019 page 50" href="http://viewer.zmags.com/publication/385363a6?page=50"> or stratification of patients. As such, they can s</a> <a title="EMJ 4.4 2019 page 51" href="http://viewer.zmags.com/publication/385363a6?page=51"> Table 2: Addressing challenges of chronic inflamma</a> <a title="EMJ 4.4 2019 page 52" href="http://viewer.zmags.com/publication/385363a6?page=52"> 2015;3(4):151-5. 4. Griffiths C et al. The glo</a> <a title="EMJ 4.4 2019 page 53" href="http://viewer.zmags.com/publication/385363a6?page=53"> Clustering by Health Professionals in Indivi</a> <a title="EMJ 4.4 2019 page 54" href="http://viewer.zmags.com/publication/385363a6?page=54"> Regarding the various forms of clustering, cluste</a> <a title="EMJ 4.4 2019 page 55" href="http://viewer.zmags.com/publication/385363a6?page=55"> How Can Clustering Effects Be Adjusted? In iRCT t</a> <a title="EMJ 4.4 2019 page 56" href="http://viewer.zmags.com/publication/385363a6?page=56"> methods, sample size, and sample size calculation</a> <a title="EMJ 4.4 2019 page 57" href="http://viewer.zmags.com/publication/385363a6?page=57"> Journal of Psychiatry and Neurosciences PubMed C</a> <a title="EMJ 4.4 2019 page 58" href="http://viewer.zmags.com/publication/385363a6?page=58"> Table 1: Baseline characteristics of the articles</a> <a title="EMJ 4.4 2019 page 59" href="http://viewer.zmags.com/publication/385363a6?page=59"> Table 2: Frequency of article allowing and/or ign</a> <a title="EMJ 4.4 2019 page 60" href="http://viewer.zmags.com/publication/385363a6?page=60"> increased over recent years, from 15% of studies </a> <a title="EMJ 4.4 2019 page 61" href="http://viewer.zmags.com/publication/385363a6?page=61"> References 1. Lee K, Thompson SG. Clustering</a> <a title="EMJ 4.4 2019 page 62" href="http://viewer.zmags.com/publication/385363a6?page=62"> A new day for genomic profiling A new world of NGS</a> <a title="EMJ 4.4 2019 page 63" href="http://viewer.zmags.com/publication/385363a6?page=63"> Immunotherapy and Oral Immunotherapy with </a> <a title="EMJ 4.4 2019 page 64" href="http://viewer.zmags.com/publication/385363a6?page=64"> life-threatening and have a major effect on the q</a> <a title="EMJ 4.4 2019 page 65" href="http://viewer.zmags.com/publication/385363a6?page=65"> leads to diminished FcεRI expression on the</a> <a title="EMJ 4.4 2019 page 66" href="http://viewer.zmags.com/publication/385363a6?page=66"> untreated group developed desensitisation t</a> <a title="EMJ 4.4 2019 page 67" href="http://viewer.zmags.com/publication/385363a6?page=67"> adverse events. Participants in the OMB group had</a> <a title="EMJ 4.4 2019 page 68" href="http://viewer.zmags.com/publication/385363a6?page=68"> At Week 44, peanut SLIT and placebo subjects comp</a> <a title="EMJ 4.4 2019 page 69" href="http://viewer.zmags.com/publication/385363a6?page=69"> Risk OIT OMB-OIT SLIT EPIT Efficacy Figure </a> <a title="EMJ 4.4 2019 page 70" href="http://viewer.zmags.com/publication/385363a6?page=70"> 24. MacGlashan DW Jr et al. Down- 3</a> <a title="EMJ 4.4 2019 page 71" href="http://viewer.zmags.com/publication/385363a6?page=71"> A Case of Lance-Adams Syndrome Post Life-Thre</a> <a title="EMJ 4.4 2019 page 72" href="http://viewer.zmags.com/publication/385363a6?page=72"> The author reports a case of LAS after a life- th</a> <a title="EMJ 4.4 2019 page 73" href="http://viewer.zmags.com/publication/385363a6?page=73"> He was brought to the emergency department with n</a> <a title="EMJ 4.4 2019 page 74" href="http://viewer.zmags.com/publication/385363a6?page=74"> Table 1: Summary of clinical and electroencephalo</a> <a title="EMJ 4.4 2019 page 75" href="http://viewer.zmags.com/publication/385363a6?page=75"> Imaging studies in diagnosing LAS have not </a> <a title="EMJ 4.4 2019 page 76" href="http://viewer.zmags.com/publication/385363a6?page=76"> 7. Lance JW, Adams RD. The syndrome 11. </a> <a title="EMJ 4.4 2019 page 77" href="http://viewer.zmags.com/publication/385363a6?page=77"> Cardiovascular Complications in Pre-eclampsia: Ca</a> <a title="EMJ 4.4 2019 page 78" href="http://viewer.zmags.com/publication/385363a6?page=78"> INTRODUCTION High maternal mortality rate (MMR) i</a> <a title="EMJ 4.4 2019 page 79" href="http://viewer.zmags.com/publication/385363a6?page=79"> points applied: ≥0.2 mV in men ≥40 years, ≥0.25 m</a> <a title="EMJ 4.4 2019 page 80" href="http://viewer.zmags.com/publication/385363a6?page=80"> to increased capillary permeability. Thes</a> <a title="EMJ 4.4 2019 page 81" href="http://viewer.zmags.com/publication/385363a6?page=81"> Parameters Odds ratio (confidence int</a> <a title="EMJ 4.4 2019 page 82" href="http://viewer.zmags.com/publication/385363a6?page=82"> for predicting the risk of cardiovascul</a> <a title="EMJ 4.4 2019 page 83" href="http://viewer.zmags.com/publication/385363a6?page=83"> Ren Fail. 2004;26(5):557-62. 9. Gaugler-Senden</a> <a title="EMJ 4.4 2019 page 84" href="http://viewer.zmags.com/publication/385363a6?page=84"> DETECT THE UNDETECTED Enhance your ability to det</a> <a title="EMJ 4.4 2019 page 85" href="http://viewer.zmags.com/publication/385363a6?page=85"> Adverse Pregnancy Outcomes in Asthmatic Women Ac</a> <a title="EMJ 4.4 2019 page 86" href="http://viewer.zmags.com/publication/385363a6?page=86"> analyses, and population-based studies have b</a> <a title="EMJ 4.4 2019 page 87" href="http://viewer.zmags.com/publication/385363a6?page=87"> on singleton deliveries from the National Registe</a> <a title="EMJ 4.4 2019 page 88" href="http://viewer.zmags.com/publication/385363a6?page=88"> Table 1 continued. 20112 2012 2013 </a> <a title="EMJ 4.4 2019 page 89" href="http://viewer.zmags.com/publication/385363a6?page=89"> Table 1 continued. 20112 2012 2013 </a> <a title="EMJ 4.4 2019 page 90" href="http://viewer.zmags.com/publication/385363a6?page=90"> commonly prescribed drug from this group (15</a> <a title="EMJ 4.4 2019 page 91" href="http://viewer.zmags.com/publication/385363a6?page=91"> Table 2 continued. N=460,3241 Without asthma n=43</a> <a title="EMJ 4.4 2019 page 92" href="http://viewer.zmags.com/publication/385363a6?page=92"> Table 3 continued. N=460,324 n Endpoint (</a> <a title="EMJ 4.4 2019 page 93" href="http://viewer.zmags.com/publication/385363a6?page=93"> Table 3 continued. N=460,324 n Endpoint (</a> <a title="EMJ 4.4 2019 page 94" href="http://viewer.zmags.com/publication/385363a6?page=94"> DISCUSSION This study evaluated two groups of del</a> <a title="EMJ 4.4 2019 page 95" href="http://viewer.zmags.com/publication/385363a6?page=95"> In the 7-year study period of prescribing habits </a> <a title="EMJ 4.4 2019 page 96" href="http://viewer.zmags.com/publication/385363a6?page=96"> References 1. Rejnö G et al. Asthma during </a> <a title="EMJ 4.4 2019 page 97" href="http://viewer.zmags.com/publication/385363a6?page=97"> The Role of the Gut Microbiome and its Derive</a> <a title="EMJ 4.4 2019 page 98" href="http://viewer.zmags.com/publication/385363a6?page=98"> Gut dysbiosis is an imbalance condition of </a> <a title="EMJ 4.4 2019 page 99" href="http://viewer.zmags.com/publication/385363a6?page=99"> baby’s gut microbiome can be influenced by nutriti</a> <a title="EMJ 4.4 2019 page 100" href="http://viewer.zmags.com/publication/385363a6?page=100"> Impaired gut barrier function Gut bacteria Co</a> <a title="EMJ 4.4 2019 page 101" href="http://viewer.zmags.com/publication/385363a6?page=101"> Based on the Asia-Pacific Working Party on N</a> <a title="EMJ 4.4 2019 page 102" href="http://viewer.zmags.com/publication/385363a6?page=102"> through the portal vein into the liver. It has be</a> <a title="EMJ 4.4 2019 page 103" href="http://viewer.zmags.com/publication/385363a6?page=103"> 14. Hasan I et al. Prevalence and risk </a> <a title="EMJ 4.4 2019 page 104" href="http://viewer.zmags.com/publication/385363a6?page=104"> Share your knowledge with the world. </a> <a title="EMJ 4.4 2019 page 105" href="http://viewer.zmags.com/publication/385363a6?page=105"> A Review of Liver Fibrosis and Emerging Therapies</a> <a title="EMJ 4.4 2019 page 106" href="http://viewer.zmags.com/publication/385363a6?page=106"> bone marrow-derived cells.3 The end result, c</a> <a title="EMJ 4.4 2019 page 107" href="http://viewer.zmags.com/publication/385363a6?page=107"> Other signalling molecules involved i</a> <a title="EMJ 4.4 2019 page 108" href="http://viewer.zmags.com/publication/385363a6?page=108"> membrane, occurring in early stages of fibrosis. T</a> <a title="EMJ 4.4 2019 page 109" href="http://viewer.zmags.com/publication/385363a6?page=109"> A variety of agents, often carcinogenic, can be e</a> <a title="EMJ 4.4 2019 page 110" href="http://viewer.zmags.com/publication/385363a6?page=110"> Table 2: Summary table of anti-fibrotic strategies</a> <a title="EMJ 4.4 2019 page 111" href="http://viewer.zmags.com/publication/385363a6?page=111"> Table 2 continued. Agent Target Mechanism</a> <a title="EMJ 4.4 2019 page 112" href="http://viewer.zmags.com/publication/385363a6?page=112"> pregnancy drug-induced cholestasis, and </a> <a title="EMJ 4.4 2019 page 113" href="http://viewer.zmags.com/publication/385363a6?page=113"> central veins, compared with control mice. T</a> <a title="EMJ 4.4 2019 page 114" href="http://viewer.zmags.com/publication/385363a6?page=114"> Thiazolidinediones Thiazolidinediones, including</a> <a title="EMJ 4.4 2019 page 115" href="http://viewer.zmags.com/publication/385363a6?page=115"> is modulated by endothelin-1 through rho-kinase-m</a> <a title="EMJ 4.4 2019 page 116" href="http://viewer.zmags.com/publication/385363a6?page=116"> 73. Cerini F et al. Enoxaparin reduces </a> <a title="EMJ 4.4 2019 page 117" href="http://viewer.zmags.com/publication/385363a6?page=117"> National Analyses on Survival in Maltese Adult </a> <a title="EMJ 4.4 2019 page 118" href="http://viewer.zmags.com/publication/385363a6?page=118"> INTRODUCTION Chronic kidney disease (CKD) requiri</a> <a title="EMJ 4.4 2019 page 119" href="http://viewer.zmags.com/publication/385363a6?page=119"> Statistical Methods The age-adjusted survival </a> <a title="EMJ 4.4 2019 page 120" href="http://viewer.zmags.com/publication/385363a6?page=120"> Methodology for Unadjusted Yearly Incidences per </a> <a title="EMJ 4.4 2019 page 121" href="http://viewer.zmags.com/publication/385363a6?page=121"> 100 90 80 70 Percentage of patients Deaths (</a> <a title="EMJ 4.4 2019 page 122" href="http://viewer.zmags.com/publication/385363a6?page=122"> Overall Survival The unadjusted survival rates fo</a> <a title="EMJ 4.4 2019 page 123" href="http://viewer.zmags.com/publication/385363a6?page=123"> relatively small numbers, although this has been </a> <a title="EMJ 4.4 2019 page 124" href="http://viewer.zmags.com/publication/385363a6?page=124"> Boosting Cancer Immunotherapies with Optical </a> <a title="EMJ 4.4 2019 page 125" href="http://viewer.zmags.com/publication/385363a6?page=125"> or improvement of the immune system to fight cance</a> <a title="EMJ 4.4 2019 page 126" href="http://viewer.zmags.com/publication/385363a6?page=126"> lymphocytes (TIL) or artificially bioengineered T </a> <a title="EMJ 4.4 2019 page 127" href="http://viewer.zmags.com/publication/385363a6?page=127"> Reducing the number of expansion cycles during th</a> <a title="EMJ 4.4 2019 page 128" href="http://viewer.zmags.com/publication/385363a6?page=128"> A) Surface plasmon resonance biosensor </a> <a title="EMJ 4.4 2019 page 129" href="http://viewer.zmags.com/publication/385363a6?page=129"> multiwell plates and imaging configuration for hig</a> <a title="EMJ 4.4 2019 page 130" href="http://viewer.zmags.com/publication/385363a6?page=130"> (A) Cell secretion assay </a> <a title="EMJ 4.4 2019 page 131" href="http://viewer.zmags.com/publication/385363a6?page=131"> stimulation is known to lead to cell rounding and</a> <a title="EMJ 4.4 2019 page 132" href="http://viewer.zmags.com/publication/385363a6?page=132"> Deliv Rev. 2019;141:3-22. </a> <a title="EMJ 4.4 2019 page 133" href="http://viewer.zmags.com/publication/385363a6?page=133"> What's New New Device for Monitoring Multiple My</a> <a title="EMJ 4.4 2019 page 134" href="http://viewer.zmags.com/publication/385363a6?page=134"> What's New Rapamycin: A Novel Anti-Ageing Cream?</a> <a title="EMJ 4.4 2019 page 135" href="http://viewer.zmags.com/publication/385363a6?page=135"> Home Testing Available for Urinary Tract Infectio</a> <a title="EMJ 4.4 2019 page 136" href="http://viewer.zmags.com/publication/385363a6?page=136"> Never miss an update again. J</a>